Esreboxetine

Small molecule

Phase 3underway

Evidence outlook · registrational

Fibromyalgia: registrational readout pending

Its supporting mid-stage studies have completed. ClinicalTrials.gov estimates the registrational readout at 2028-03; company guidance (Axsome Therapeutics, stated 2026-11-02): topline data expected 3Q 2027.

Company guidance: topline data expected 3Q 2027 (NCT07398417; Axsome Therapeutics, 2 Nov 2026). “AXS-14 for the management of fibromyalgia Key eligibility criteria ≥18 years of age with diagnosis of fibromyalgia Primary endpoint Time from randomization to loss of therapeutic response FORWARD Phase 3 trial Placebo AXS-14 (8 mg) Open-label period (12 weeks) Double-blind phase (up to 12 weeks) Baseline 1:1 R AXS-14 (8 mg) 1:1 randomization (Patients achieving treatment response) 45 Enrollment completion anticipated 3Q 2027” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (6)
Fibromyalgia
NCT00796601 · Pfizer
2009-05-01 – 2010-11-01 · Fibromyalgia
What this study did
NCT00607256 · Pfizer
2007-10-20 – 2009-05-18 · Fibromyalgia
What this study did
NCT00754221 · Pfizer
2008-05 – 2009-05 · Fibromyalgia
What this study did
Phase 2 (1)
Fibromyalgia
Phase 1 (2)
Fibromyalgia
NCT00809289 · Pfizer
2008-12 – 2009-07 · Fibromyalgia
What this study did
Other / comorbidity
NCT00800956 · Pfizer
2009-01 – 2009-02 · Healthy
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, 1 of them ahead of this one.

This drug's own stage for Fibromyalgia: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Esreboxetine: this drugPhase 3Small moleculenorepinephrine transporternot yet gradedNo reviewed efficacy summary in this indication
Cyclobenzaprine (Tonmya)ApprovedSmall molecule5-HT2A, α1-adrenergic, H1-histaminergic, and M1-muscarinic acetylcholine receptors (functional antagonism)Partial signal
NCT04172831: Change in weekly average daily pain (NRS) from baseline to week 14: TNX-102 SL 5.6 mg -1.9 vs placebo -1.5; LS mean difference -0.4 (95% CI -0.7 to -0.1), p=0.010 (n=248 and 255) (CT.gov posted results).
NCT04508621: Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores. (14 weeks): TNX-102 SL Tablet, 5.6 mg -1.6 score on a scale (95% CI -1.8 to -1.3) | Placebo SL Tablet -1.3 score on a scale (95% CI -1.5 to -1.1) missed
Duloxetine (Cymbalta)ApprovedSmall moleculeSerotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET)not yet gradedNo reviewed efficacy summary in this indication
PregabalinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsnot yet gradedNo reviewed efficacy summary in this indication
Viloxazine (Qelbree)
Approved(overall)
Small moleculenorepinephrine transporter
Reliable signal(overall)
No reviewed efficacy summary in this indication
Reboxetine
Phase 3(overall)
Small moleculenorepinephrine transporter
Partial signal(overall)
No reviewed efficacy summary in this indication
ONO-1110Phase 2Small moleculeEndocannabinoid synthesisnot yet gradedNo reviewed efficacy summary in this indication
Ampreloxetine (TD-9855)
Discontinued
Small moleculenorepinephrine transporter
Partial signal(overall)
No reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Esreboxetine to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (2)
March 2028 (1)
Phase 3FibromyalgiaRecruiting
Est. primary completion 2028-03 · NCT07398417 · CT.gov ↗

Company guidance: topline data expected 3Q 2027 (Axsome Therapeutics, 2 Nov 2026). “AXS-14 for the management of fibromyalgia Key eligibility criteria ≥18 years of age with diagnosis of fibromyalgia Primary endpoint Time from randomization to loss of therapeutic response FORWARD Phase 3 trial Placebo AXS-14 (8 mg) Open-label period (12 weeks) Double-blind phase (up to 12 weeks) Baseline 1:1 R AXS-14 (8 mg) 1:1 randomization (Patients achieving treatment response) 45 Enrollment completion anticipated 3Q 2027” Source ↗

What to watch
May 2028 (1)
Phase 3FibromyalgiaEnrolling by invitation
Est. primary completion 2028-05 · NCT07637162 · CT.gov ↗
What to watch

See the full readout calendar ↗